PMGC Holdings (ELAB) Share-based Compensation (2022 - 2026)
PMGC Holdings' (ELAB) quarterly Share-based Compensation came in at $1.1 million in Q2 2026, up 7005.78% year-over-year from $15842.0 in Q2 2025, and up 142.91% quarter-over-quarter from $463421.0 in Q1 2026.
Analysis
PMGC Holdings (ELAB) Share-based Compensation (2022 - 2026) Analysis & Trends
PMGC Holdings has disclosed Share-based Compensation across 5 years of filings, most recently posting $1.1 million for Q2 2026.
- In Q2 2026, Share-based Compensation rose 7005.78% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $1.1 million (up 896.63% YoY), while the FY2025 annual figure was $36616.0, down 94.66% from the prior year.
- Share-based Compensation came in at $1.1 million for Q2 2026 at PMGC Holdings, up from $463421.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $35.6 million in Q3 2022 to a low of -$93.9 million in Q4 2022.
- Average Share-based Compensation over 5 years is -$3.2 million, with a median of $125548.5 recorded in 2023.
- Year-over-year, Share-based Compensation tumbled 103.78% in 2025 and soared 7005.78% in 2026.
- Over 5 years, Share-based Compensation stood at -$93.9 million in 2022, then surged by 100.15% to $141190.0 in 2023, then tumbled by 89.55% to $14756.0 in 2024, then surged by 350.21% to $66433.0 in 2025, then soared by 1594.49% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $1.1 million in Q2 2026, $463421.0 in Q1 2026, and $66433.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.40 Bn | 192.42 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 180.38 Bn | 177.20 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.43 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.73 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.28 Bn | 55.09 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.02 Bn | 48.88 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.28 Bn | 29.97 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.81 Bn | 30.52 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.02 Bn | 29.02 Bn | 1.16 Mn | 83.34 Mn |
| 10 | PMGC Holdings | 2.29 Mn | -16.50 Mn | 385,691.00 | 1.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Mar 31, 2026 | 463,421.00 |
| Dec 31, 2025 | 66,433.00 |
| Sep 30, 2025 | 13,180.00 |
| Jun 30, 2025 | 15,842.00 |
| Mar 31, 2025 | -58,838.00 |
| Dec 31, 2024 | 14,756.00 |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.56 Mn |
| Dec 31, 2023 | 141,190.00 |
| Sep 30, 2023 | 1.54 Mn |
| Jun 30, 2023 | 109,907.00 |
| Mar 31, 2023 | 75,161.00 |
| Dec 31, 2022 | -93.93 Mn |
| Sep 30, 2022 | 35.59 Mn |